The goal of many current studies of neovascularization is to define the phenotype of vascular cell populations of different origins and to determine how such cells promote assembly of vascular channel. Here, we describe a protocol to immunophenotype vascular cells by high-resolution imaging and by fluorescence-activated flow cytometry in an in vivo rodent model of pulmonary microvascular remodeling. Analysis of cells by this combined approach will characterize their phenotype, quantify their number and identify their role in the assembly of vascular channels.
INTRODUCTION
Currently, the phenotype and role of vascular cell populations of different origins in blood vessel formation and repair in adult tissues is of great interest. We have developed a protocol to study the kinetics of these cells using a rodent model of vascular remodeling (of vessels and/or capillaries) after hyperoxic acute lung injury (HALI 1 and accompanying Nature Protocol by Jones et al. 2 ). Briefly, in the model, injured small vessels (in rat lung) increase their wall thickness (10-fold) and disrupted capillary networks (in rat and mouse lung) subsequently reform 1, 3 . Here, we describe high-resolution immunogold-labeling approaches for phenotyping and quantifying cells in situ in these vascular structures, and the use of fluorescenceactivated flow cytometry to phenotype and quantify cells of interest circulating in blood or present in dissociated lung tissue. Both approaches will identify precursor vascular cell populations. The HALI model allows the cellular basis of this response to be analyzed [3] [4] [5] . Cells are readily characterized by their morphology and location as intravascular (circulating through the lung) or resident in vascular structures such as endothelial cells, pericytes, smooth muscle cells or perivascular fibroblasts, in high-resolution images (the gold standard to identify cell type). Antibodies to vascular growth factor ligands and receptors such as VEGFR-VEGF-R2 or PDGF-BB-PDGF-Rb, or to cluster differentiation (CD) marker proteins such as CD11b or CD31, will further establish the phenotype of the cell populations targeted in high-resolution images or by fluorescence activated flow cytometry [4] [5] [6] . Immunophenotypic data obtained by fluorescence microscopy and flow cytometry are, at one level, suitable to characterize cell populations by their origin; however, these data lack sufficient resolution (fluorescence microscopy) or are unable (flow cytometry) to determine their precise location in situ and their contribution to vascular remodeling. The techniques of high-resolution imaging and flow cytometry can, by contrast, provide significant insight into the role of cells' remodeling vascular structures as well as determining their origin and phenotype. Thus, although the two methodologies can be employed separately to identify vascular precursors, we use both in this protocol because of the complementary results the data provide.
MATERIALS

REAGENTS
. 10Â Dulbecco's phosphate-buffered saline (PBS; Gibco/Invitrogen, cat. no.
14200-075)
. Ethanol, 95% (AAPER Alcohol & Chemical Co., cat. no. 04 H12QB) . Ethanol, 100% (AAPER Alcohol & Chemical Co., cat. no. 04 I13BA) . Unique acrylic resin (Unicryl), 4% mono-methacrylate esters/4% styrene kit (EMS, cat. no. 14660) . Toluidine blue (Ernest Fullam, cat. no. 50180) . Sodium borate (Fisher Scientific, cat. no. S-248) . Permount mounting medium (Fisher Scientific, cat. no. . Distilled/deionized water . Bovine serum albumin (BSA; Amersham, cat. no. RPN412) . Purified antibodies (e.g., anti-aSMA, Sigma, cat. no. A2547; anti-PDGF-BB, . Purified anti-rat PDGF-Rb (425-446) rabbit antibody (Calbiochem, EMD Biosciences or similar products) or anti-mouse PDGF-Rb-PE rat antibody (eBioscience, cat. no. 12-1402 or similar products)
. PE-Cy5-labeled anti-rat CD45 mouse antibody (BD Pharmingen, cat. no.
or similar products)
. . Water bath with shaker (e.g., Cox machine) . Seward Stomacher compact blender (Cole-Parmer, cat. no. EW-36850-00) . Rodents (a minimum of 3-4 rats or mice for each time point studied) that have breathed high oxygen or high oxygen followed by air, as described for our model of lung neovascularization [1] [2] [3] [4] [5] 7 . For Steps 1-34 of this protocol, use fixed rodent lung tissue prepared as described 2 ; for Steps 35-56, use freshly excised rodent lung tissue and/or blood ! CAUTION Experiments using live rodents must conform to local and national regulations.
. Disposable 
PROCEDURE
Preparation of lung tissue in Unicryl resin 1| From fixed rodent lung tissue (see EQUIPMENT) prepare 3 mm 3 blocks and store overnight in fresh 3% paraformaldehyde/ 0.1% gluteraldehyde at 4 1C.
2|
Put the shell vials with the tissue into metal vial holders and place in a plastic container surrounded with crushed ice. m CRITICAL STEP To obtain consistent (and optimal) dehydration of tissue, the vials must remain in this container on crushed ice throughout the following steps. 7| Infiltrate tissue in cold 100% Unicryl for 1 h at À20 1C. Repeat in fresh cold Unicryl for 1 h at À20 1C. ! CAUTION Store Unicryl at À20 1C in double Ziploc plastic bags for transfer between the hood and freezer. Similarly, after adding Unicryl to the tissue, place the complete plastic container with holders, vials and ice into double Ziploc plastic bags and seal the bags before transferring between the hood and the À20 1C refrigerator.
8| Infiltrate tissue in fresh 100% Unicryl overnight at À20 1C.
9|
The next morning, layer crushed ice in the PELCO cryochamber, cover the wet ice with dry-ice pellets and allow the chamber to cool to À20 1C (this will take B4 h).
10| Insert clean BEEM capsules into labeled BEEM cryocapsule holders, fill the capsules with fresh cold Unicryl and transfer the tissue blocks into the capsules with an applicator stick and (after ensuring that the blocks sink to the bottom of the capsule) close the cap.
11| Place the cryocapsule holders on the metal support rods inside the cryochamber, close the chamber top, check that the temperature is À20 1C and turn on the air-circulating fan and the UV light to polymerize the resin. m CRITICAL STEP Monitor the temperature in the chamber throughout the day; when needed, add more ice to maintain the temperature at À20 1C. Overnight it can range from À20 1C to 10 1C, so always plan to add more ice early in the morning on the next day. Temperatures consistently lower than À20 1C will speed polymerization but lead to poor infiltration of the tissue by the resin.
12|
After approximately 48 h, test a sample of resin blocks distributed throughout the chamber for sufficient hardness (open each capsule and tap with an applicator stick) and, when polymerization is complete, leave the capsules in the open chamber overnight to dissipate residual odor.
13| Cut the BEEM capsule away from the polymerized tissue block with a single-edge industrial blade, and label the block with a permanent ink marker. ' PAUSE POINT These blocks are stable and can be stored at RT indefinitely.
Preparation of lung tissue sections 14| Under a stereomicroscope, use a single-edge industrial blade to remove excess resin from the surface of the block and ( just) expose the tissue face.
15| As a prelude to cutting 90-nm-thick sections, collect 2-3 1-mm-thick sections on a glass slide, gently dry on a hotplate, stain with 0.1% toluidine blue, rinse with distilled/deionized water and mount under a coverslip using Permount. Check the tissue face by bright-field microscopy; when appropriate, that is, when the tissue face contains vessels or capillary networks of interest, proceed to cut 90-nm-thick sections.
16| Collect a series of 90-nm-thick sections onto Formvar-coated nickel grids with a (locking) Dumont tweezer, and place the tweezers with the grids in a closed Petri dish to air dry. ' PAUSE POINT Store and catalogue these grids (with attached unstained tissue sections) in calibrated grid storage boxes until proceeding with immunogold labeling and high-resolution imaging. Plan on using these within weeks.
Immunogold labeling of lung tissue sections for high-resolution imaging 17| Place a strip of Parafilm on the rubber plate of a staining box and float Formvar-coated nickel grids (with tissue sections) face down in 1Â PBS for 5 min (keep it covered to exclude dust particles). m CRITICAL STEP Immediately before use, filter distilled/deionized water, PBS and staining solutions through Millex syringe-driven filters to minimize contamination by extraneous particulates. Transfer grids (with 90-nm-thick sections) using (locking) Dumont forceps, and rinse the forceps well between solutions to minimize cross-contamination.
18| Blot off excess PBS with filter paper strips and treat with 1% BSA in 1Â PBS for 5 min to block endogenous/nonspecific tissue sites from reacting with the antibody.
19|
Further block in 0.5% BSA in 1Â PBS for 2 min.
20| Incubate in primary antibody (e.g., anti-aSMA, anti-PDGF-BB, anti-PDGF-Rb, anti-CD11b and anti-VEGF-R2) diluted in 0.5% BSA in 1Â PBS for 2 h at RT, or overnight at 4 1C (add a wet gauze pad to the staining box to make a humid chamber, if incubated overnight). 21| Place all grids/sections in a clean drop of 1Â PBS to halt the antibody reaction.
22| Pick up each grid/section with clean Dumont tweezers, wick off excess moisture from the grid with filter paper strips and rinse with 1Â PBS; place each grid/section onto a clean drop of 1Â PBS in the staining chamber, and rotate the chamber (on a rotomix) for 5 min. Repeat three times.
23| Wick off excess 1Â PBS and incubate the grids/sections in 0.5% BSA in 1Â PBS for 5 min. 26| Collect each grid/section with a (locking) Dumont tweezer and place (the grid/section and tweezer) in a closed Petri dish to air dry. Grids with pA-AU-labeled antigenic sites can be treated with an optional silver aggregate procedure to enhance labeling (see Box 1). m CRITICAL STEP To verify/validate the pA-AU result carry out the following steps: run appropriate negative control grids (concurrently) with Steps 17-26, for example; omit the antibody and incubate directly with the pA-AU to identify nonspecific adsorption of pA-AU to the section; incubate the section with IgG-rich plasma and the pA-AU complex to identify the ability of the pA conjugate to bind endogenous immunoglobulins; incubate the section with antigen-adsorbed antibody solution followed by the pA-AU complex to identify nonspecific antigen-antibody interactions; pretreat the antibody with a commercially available neutralizing peptide to block the reaction. ' PAUSE POINT The dry grids can be left overnight. Double-staining cell membranes to enhance (electron) density 27| Place each grid/section in a drop of 7.5% aqueous uranyl magnesium acetate for 20 min.
28| Rinse in distilled/deionized water and rotate for 10 min. Repeat twice.
29| Place each grid/section in a drop of 0.2% aqueous lead citrate for 5 min.
30| Rinse in distilled/deionized water and rotate for 10 min. Repeat twice.
31| Collect each grid/section with a (locking) Dumont tweezers and place in a closed Petri dish to air dry. ' PAUSE POINT Stained grids/sections can be viewed repeatedly if carefully handled and stored in calibrated grid boxes to ensure reliable retrieval. Analysis of immunogold-labeled cells 32| Examine the stained grids/sections by TEM (typically use a magnification of Â6,689 to Â9,818 to identify cell phenotype by morphology/organelles and position in a vessel or capillary wall, and magnifications from Â12,480 to Â19,636 to identify pA-AU-labeled antigenic sites).
33| Collect a library of high-resolution images of cells forming vessel or capillary walls.
34| Analyse images. Both images collected digitally or scanned from standard (3 inch Â 4 inch) negatives are suitable for analysis; digital images facilitate quantitative analyses of antigenic sites (see Box 2 and Fig. 1 ), whereas the size (diameter) of a vessel, or of a capillary area of interest, is best determined from a standard negative.
Preparation of cell suspensions from blood and lung tissues 35| Draw (a minimum of) 1 ml of peripheral blood from rodents by cardiac puncture, and immediately transfer into EDTA collection tubes to prevent platelet degranulation. Keep the samples on wet ice at all times and process within 2-3 h of collection, as described in Steps 36-40.
36|
Centrifuge fresh samples at 700g for 20 min at 4 1C (with no brake).
37| Gently remove the upper phase (plasma) with a 1 ml pipette tip (plasma can be stored in 0.25 ml aliquots for plasma protein measurements).
38|
Resuspend the lower phase containing the blood cells using 5 ml of cold 1Â PBS containing 0.5% (wt/vol) BSA and 1.5 mM EDTA. (iii) Assess the density of antigenic sites associated with a given cell using the NIH-supported, public domain, java-based, application ImageJ 1.38, which can be downloaded at http://www.rsb.info.nih.gov/ij/. The protocol notation refers to 'menu'/'command' . So, for example, the 'Sharpen' command is found under the 'Process' menu. To automate the process, these steps can readily be incorporated into a macro with a single command. As we are interested in the antigen density on a given cell, we first make a selection using the free selection tool in ImageJ to enclose the area of interest. Once this is done, the processing and analysis can be performed. Figure 1 shows a representative raw image (Fig. 1a) and the results of processing and analysis (Fig. 1b) . (xiv) The data can be viewed by selecting Window/Summary. Results listed include the file name, the number of particles ('Count'), the selected area ('Total Area'), the 'Average Particle Size' and the 'Area Fraction' (the number of pixels associated with particles divided by the selected area). The relevant parameter for most studies is the gold particle density, which can be calculated as the number of particles divided by the selected area. Length scales can be calibrated within ImageJ (by choosing Analyze/Set Scale), or postanalysis if the number of nanometers per pixel is known (by multiplying the area in pixels by N 2 , where N is the number of nanometers per pixel).
39| Centrifuge samples at 700g for 20 min at 4 1C (with no brake).
40|
Remove the upper phase and discard it; resuspend the cell pellet by gentle pipetting or vortex, and transfer 0.6 ml into a separate tube and keep on ice. ! CAUTION Lengthy storage of samples, or their maintenance at RT, is not recommended as it may affect cell phenotype.
41| Wash freshly excised rodent lungs in 1Â PBS.
42| Cut the lung into small pieces (B1-2 mm in diameter) using scissors. 44| Filter the tissue homogenate (through a 100 mm filter) into another 50 ml tube.
45|
Centrifuge the samples at 700g for 20 min at 4 1C.
46|
Resuspend the cells using 20 ml of cold 1Â PBS.
47|
Centrifuge the cells at 700g for 20 min at 4 1C.
48|
Resuspend the cells using 5 ml of cold 1Â PBS and keep on ice.
Immunostaining cells for multicolor flow cytometry 49| Immunostain cell suspensions obtained from lung samples or blood from rats (option A) or mice (option B). m CRITICAL STEP It is recommended that antibody lots should be first tested for activity with positive control samples before experimental samples are assayed. For hematopoietic markers such as CD45 and CD11b, peripheral blood cells are the ideal test samples; staining with these markers should delineate clear positive and negative populations. For VEGF-R2, primary or immortalized endothelial cell lines can be used to test for activity; however, the degree of staining intensity will differ between adherent, purified, cultured and circulating cells. Fc blocking (when using the PDGF-Rb antibody) is important to prevent nonspecific binding common to many cell types, including B lymphocytes, natural killer cells, granulocytes, monocytes, macrophages and platelets. Commercially available VEGF-R2 and PDGF-Rb antibodies for mouse were conjugated to fluorophores, whereas the ones available for rat were not, necessitating additional steps (see Steps A(vi) and (vii)) for adding a fluorophore, that is, FITC-goat anti-rabbit IgG.
(A) For rat samples.
(i) Place 200 ml of blood or lung tissue cell samples into one isotype control and two sample 15 ml tubes. Add 1 mg ml À1 Fc-receptor-blocking agent; incubate the sample on ice for 10 min. (ii) Add the following fluorophore-labeled antibodies:
Tube 1 (isotype control), 1 ml IgG-FITC, 1 ml IgG-PE, 1 ml IgG-PE-Cy5 and 1 ml IgG-allophycocyanin (APC); Tube 2 (sample), 1 ml (purified) VEGF-R2 antibody, 1 ml CD11b-PE and 1 ml of CD45-PE-Cy5; Tube 3 (sample), 1 ml (purified) PDGF-Rb antibody, 1 ml CD11b-PE and 1 ml CD45-PE-Cy5. (iii) For additional studies of lung cell phenotype, prepare extra tubes. m CRITICAL STEP During the first run, it is important to run single-color controls to set up the compensation matrix. Cell viability can be tested using nuclear dyes, such as the DNA intercalator propidium iodide (replaces the PE antibody) or monomeric cyanine dyes (To-Pro-3, far-red channel). If using fluorescence-labeled antibodies from other manufacturers, the concentration should be optimized by testing serial concentrations to achieve similar staining patterns. (iv) Vortex briefly and incubate for 30 min at 4 1C, or on ice in the dark. (i) Place 200 ml of blood or digested lung tissue samples into one isotype control and two sample 15 ml tubes.
(ii) Add the following fluorophore-labeled antibodies: Tube 1 (control), 1 ml IgG-FITC, 1 ml IgG-PE and 1 ml IgG-peridinin-chlorophyll-protein complex (PerCP); Tube 2 (sample), 1 ml CD31-FITC, 1 ml VEGF-R2-PE, 1 ml CD45-PerCP, 1 ml CD11b-APC; Tube 3 (sample), 1 ml CD31-FITC, 1 ml PDGF-Rb-PE, 1 ml CD45-PerCP, 1 ml of CD11b-APC. 50| Lyse RBCs in rat and mouse samples; first add 2 ml of ACK lysing buffer, vortex briefly and incubate at RT (18-25 1C) for 3 min. It may not be necessary to remove RBCs from tissue cell suspension but it would be helpful as it is often hard to completely avoid some RBC contamination. m CRITICAL STEP Lysis should not be performed for more than 3-5 min as it may affect cell viability.
51| Wash once with 5 ml cold 1Â PBS and centrifuge at 250g at 4 1C (with brake) for 5 min to remove the supernatant.
52|
Resuspend the cell pellet in 400 ml 1Â PBS and filter the samples through 40 mm cell strainer into 5 ml BD Falcon tubes and label the tubes with the staining combination information.
53|
To assess viability, after washing, resuspend the pellet in 1 ml 1Â PBS containing 20 mg ml À1 of viability dye, gently mix the suspension, incubate for approximately 20 min at 4 1C (in the dark) and run the samples on the flow cytometer in their staining solution. Use single-color control tubes with the viability dye only. m CRITICAL STEP All tubes should be kept at 4 1C (or on ice) in the dark before acquisition on the flow cytometer and should be run within 1 h after the addition of the dye. If the samples are not run immediately, the samples should be fixed in 2% paraformaldehyde to ensure optimal results. Samples should not be exposed to light as bleaching of the fluorophores may occur.
Flow cytometry analysis of blood or lung tissue cells 54| Set the gate of the flow cytometer for the sample to be analyzed (the analysis of blood and lung cells will differ only in this step). For 'blood samples,' set the gate on lymphocytes and monocytes (mononuclear cells) to avoid any RBC, platelet, cell debris and neutrophil contamination. Lymphocytes have low forward scatter (FSC) and side scatter (SSC), monocytes have high FSC and low SSC and neutrophils have high FSC and SSC characteristics. Collect at least 100,000-150,000 events in the mononuclear or cellular gate.
For 'tissue cell suspensions,' gate on all cell size events. Individual cell populations cannot be defined using FSC and SSC. Therefore, set the gate on cell size events (see Fig. 2 ). This can be estimated by using the FSC characteristics of lymphocytes defined by the above peripheral blood samples. Collect 100,000-150,000 events in the mononuclear or cellular gate. m CRITICAL STEP Save the settings for interchannel compensation and analysis and use for all samples, but set the gate individually for each sample on the mononuclear cell populations to exclude any contamination by neutrophil, platelet, RBC or cell debris (see Fig. 2 ). Flow-cytometric samples must be properly compensated; proper compensation techniques can be referenced using general flow cytometry textbooks or online sources (http://www.bdbiosciences.com/immunocytometry_systems/support/training/online/ITF/start.html and http://www.flowjo.com/v6/reference.html).
55| First, run the isotype-stained control sample with voltages set so that a majority of events are in the left lower quadrant. Next, run each single-color fluorochrome control. Signal that bleeds from one channel into an adjacent channel can be removed using the Cellquest software during sample acquisition. Likewise, care must be taken so as not to overcompensate the samples. Alternatively, the data from single-color controls can be used to set up a compensation matrix at a later time using software programs such as Flowjo. 
ANTICIPATED RESULTS
Immunophenotype of cells remodeling vascular structures in situ in rodent lung Cell types in normal lung, and the ones participating in vessel remodeling (in rat) and capillary remodeling (in rat and mouse), are identifiable in high-resolution images by their morphology 1 (see also accompanying Nature Protocol by Jones et al. 2 ). The presence of antigenic sites on these cells-detected by the panel of primary antibodies used, for example, VEGF-R2, aSMA, SMM-HC, PDGF-A, PDGF-B, PDGF-Ra, PDGF-Rb (Fig. 3) or CD11b is visualized by the distribution of electron-dense particles 4, 5, 7, 8 . This will characterize the immunophenotype of the cells forming vessel and capillary walls. For example, the precursor smooth muscle cells (i.e., interstitial fibroblasts) developing in vessel walls of the high-oxygen-injured lung are shown by this approach to acquire a characteristic 'contractile' smooth muscle phenotype by expressing aSMA and SMM-HC 7, 8 . Quantifying the density of gold particles over vascular and precursor cells (by a macro) detects shifts in the expression of specific proteins 4, 5 . Studies of the ligand-tyrosine kinase receptor-mediated basis of the response, as shown by the use of antibodies to PDGF-A-PDGF-Ra or PDGF-B-PDGF-Rb, demonstrate a shift in phenotype of these precursor cells, and of other adjacent vascular cells, in the high-oxygen-injured lung 4, 5 (Fig. 4) . Based on quantitative data clearly demonstrating the development of high numbers of PDGF-Rb + vascular precursor cells 5 , the use of a specific PDGF-Rb-blocking agent to prevent this response points to a potential therapeutic strategy. Similar studies can be performed for endothelial precursor cells responsible for vessel and capillary remodeling. 
